Empiric and Trigger-Guided Superior Vena Cava Isolation in AF Ablation: Systematic Review and Meta-Analysis.

Pacing Clin ElectrophysiolMay 19, 2026 (epub)
Clinical ResearchCardiology

Ojasav Sehrawat, Vasudha Garg, Cher Ying Foo et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of empiric versus trigger-guided superior vena cava isolation (SVCI) in atrial fibrillation (AF) ablation. Analyzing data from eight randomized controlled trials involving 1231 patients, the study found that empiric SVCI significantly reduced atrial tachyarrhythmia recurrence compared to pulmonary vein isolation (PVI) alone (RR 0.70, 95% CI 0.53-0.92; p = 0.01).

Key findings

  • SVCI+PVI reduced recurrence of atrial tachyarrhythmia compared to PVI alone (97/604 vs. 135/627; RR 0.77, p = 0.03).
  • Empiric SVCI significantly reduced recurrence (RR 0.70, p = 0.01), while trigger-guided SVCI did not show significant benefit (RR 0.80, p = 0.57).
  • In paroxysmal AF, adjunctive SVCI significantly reduced recurrence (RR 0.68, p = 0.01).
  • Major complications were numerically higher with SVCI+PVI (15/604 vs. 7/627; RR 1.96, p = 0.10).

Why it matters

Understanding the comparative effectiveness of empiric versus trigger-guided SVCI can inform clinical decision-making in AF ablation, potentially improving patient outcomes by reducing recurrence rates.

Source

PubMed · PMID 42154216

Published in Pacing Clin Electrophysiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.